Indivior Plc - Company Profile
Powered by 
All the data and insights you need on Indivior Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Indivior Plc Strategy Report
- Understand Indivior Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Indivior Plc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| 27 Jul 2021 | Indivior Plc Enters Phase I Clinical Trial Agreement with Altasciences Co Inc for (buprenorphine hydrochloride + naloxone hydrochloride), INDV-2000 (GDCT0419791) | Contract Service Agreement |
Indivior Plc
|
Altasciences Co Inc
|
| 08 Jun 2021 | Indivior to Enter into Licensing Agreement with Aelis Farma | Licensing Agreement |
Aelis Farma SAS
|
Indivior Plc |
| 16 Sep 2020 | Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder | Grant |
National Institute on Drug Abuse
|
Indivior Inc
|
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer